Top

Published in:

Open Access 01-02-2019

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir

Authors: Kevin Robertson, Paul Maruff, Lisa L. Ross, David Wohl, Catherine B Small, Howard Edelstein, Mark S. Shaefer

Published in: Journal of NeuroVirology | Issue 1/2019

Abstract

Human immunodeficiency virus (HIV)-associated neurocognitive disorders can persist in many patients despite achieving viral suppression while on antiretroviral therapy (ART). Neurocognitive function over 48 weeks was evaluated using a Cogstate test battery assessing psychomotor function, attention, learning, and working memory in 293 HIV-1-infected, ART-experienced, and virologically suppressed adults. The ASSURE study randomized participants 1:2 to remain on tenofovir/emtricitabine (TDF/FTC) and ritonavir-boosted atazanavir (ATV/r) or simplify to abacavir/lamivudine + atazanavir (ABC/3TC + ATV). Neurocognitive z-scores were computed using demographically adjusted normative data and were classified as “impaired” (defined as either a z-score ≤ − 2 or having 2 or more standardized individual test z-scores ≤ − 1); while higher scores (equaling better performance) were classified as “normal”. By z-scores, 54.7% of participants had impaired neurocognition at baseline and 50.2% at week 48. There were no significant differences (p < 0.05) in the baseline-adjusted performance between treatment groups for any individual test or by z-score. Specific demographic and medical risk factors were evaluated by univariate analysis for impact on neurocognitive performance. Factors with p < 0.10 were evaluated by backwards regression analysis to identify neurocognition-correlated factors after accounting for treatment, assessment, and baseline. Four risk factors at baseline for impaired neurocognition were initially identified: lower CD4 nadir lymphocyte counts, higher Framingham risk scores, and interleukin-6 levels, and a history of psychiatric disorder not otherwise specified, however none were found to moderate the effect of treatment on neurocognition. In this aviremic, treatment-experienced population, baseline-adjusted neurocognitive function remained stable and equivalent over 48 weeks with both TDF/FTC + ATV/r-treated and in the ART-simplified ABC/3TC + ATV treatment groups.

Arenas-Pinto A, Stohr W, Jager R, Haddow L, Clarke A, Johnson M, Chen F, Winston A, Godi C, Thust S, Trombin R, Cairns J, Solanky BS, Golay X, Paton NI, PIVOT Neurocognitive sub-study Team (2016) Neurocognitive function and neuroimaging markers in virologically suppressed HIV-positive patients randomized to ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional substudy from the PIVOT trial. Clin Infect Dis 63:257–264. https://doi.org/10.1093/cid/ciw279 CrossRefPubMedPubMedCentral

Bloch M, Kamminga J, Jayewardene A, Bailey M, Carberry A, Vincent T, Quan D, Maruff P, Brew B, Cysique LA (2016) A screening strategy for HIV-associated neurocognitive disorders that accurately identifies patients requiring neurological review. Clin Infect Dis 63:687–693. https://doi.org/10.1093/cid/ciw399 CrossRefPubMedPubMedCentral

Cohen J (1988) Statistical power analysis for the behavioral sciences, 2nd edn. Lawrence Erlbaum, Hillsdale, New Jersey

Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Günthard HF, Swiss HIV Cohort Study (2013) Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid. J Acquir Immune Defic Syndr 62:28–35. https://doi.org/10.1097/QAI.0b013e318274e2b0 CrossRefPubMed

Cysique LA, Maruff P, Brew BJ (2004) Antiretroviral therapy in HIV infection: are neurologically active drugs important? Arch Neurol 61:1699–1704. https://doi.org/10.1001/archneur.61.11.1699 CrossRefPubMed

Cysique LA, Maruff P, Darby D, Brew BJ (2006) The assessment of cognitive function in advanced HIV-1 infection and AIDS dementia complex using a new computerised cognitive test battery. Arch Clin Neuropsychol 21:185–194. https://doi.org/10.1016/j.acn.2005.07.011 CrossRefPubMed

Cysique LA, Maruff P, Bain MP, Wright E, Brew BJ (2011) HIV and age do not substantially interact in HIV-associated neurocognitive impairment. J Neuropsychiatry Clin Neurosci 23:83–89. https://doi.org/10.1176/jnp.23.1.jnp83 CrossRefPubMed

De Luca A, Ciancio BC, Larussa D, Murri R, Cingolani A, Rizzo MG, Giancola ML, Ammassari A, Ortona L (2002) Correlates of independent HIV-1 replications in the CNS and of its control by antiretrovirals. Neurology 59:342–347CrossRefPubMed

DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents (2018) Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Available at https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed April 4, 2018

Elion R, Berger D, Richmond G, Sension M, Dejesus E, Cimoch P, St Clair M, Yau L, Ha B, Col102060 Study Team (2010) Simplified maintenance therapy with abacavir/lamivudine and atazanavir after discontinuation of ritonavir. HIV Clin Trials 11:170–173. https://doi.org/10.1310/hct1103-170 CrossRefPubMed

Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, Collier AC, Gelman B, McArthur J, Morgello S, McCutchan JA, Grant I, CHARTER Group (2011) CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS 25:1747–1571. https://doi.org/10.1097/QAD.0b013e32834a40cd CrossRefPubMed

Garvey L, Surendrakumar V, Winston A (2011) Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials 12:333–338. https://doi.org/10.1310/hct1206-333 CrossRefPubMed

Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E, SWAN Study Group (2007) Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN study (AI424-097) 48-week results. Clin Infect Dis 44:1484–1492. https://doi.org/10.1086/517497 CrossRefPubMed

Ghosn J, Carosi G, Moreno S, Pokrovsky V, Lazzarin A, Pialoux G, Sanz-Moreno J, Balogh A, Vandeloise E, Biguenet S, Leleu G, Delfraissy JF (2010) Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as ritonavir-boosted regimen. Antivir Ther 15:993–1002. https://doi.org/10.3851/IMP1666 CrossRefPubMed

Giancola ML, Lorenzini P, Balestra P, Larussa D, Baldini F, Corpolongo A, Narciso P, Bellagamba R, Tozzi V, Antinori A (2006) Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 41:332–337. https://doi.org/10.1097/01.qai.0000197077.64021.07 CrossRefPubMed

Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls AP, Boardley RL, Berges AC, Nathan PJ, Horrigan JP (2014) A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer’s disease. Curr Alzheimer Res 11:47–58CrossRefPubMed

Haddow LJ, Laverick R, Daskalopoulou M, McDonnell J, Lampe FC, Gilson R, Speakman A, Antinori A, Balestra P, Bruun T, Gerstoft J, Nielsen L, Vassilenko A, Collins S, Rodger AJ, Cognitive Impairment in People with HIV in the European Region (CIPHER) Study Group (2017) Multicenter European prevalence study of neurocognitive impairment and associated factors in HIV positive patients. AIDS Behav 22:1573–1583. https://doi.org/10.1007/s10461-017-1683-z CrossRefPubMedCentral

Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, Ellis RJ, Letendre SL, Marcotte TD, Atkinson JH, Rivera-Mindt M, Vigil OR, Taylor MJ, Collier AC, Marra CM, Gelman BB, McArthur JC, Morgello S, Simpson DM, McCutchan JA, Abramson I, Gamst A, Fennema-Notestine C, Jernigan TL, Wong J, Grant I, CHARTER Group (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 75:2087–2096. https://doi.org/10.1212/WNL.0b013e318200d727 CrossRefPubMedPubMedCentral

Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K, AIDS Clinical Trials Group 736 Study Team (2009) Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 23:1359–1366. https://doi.org/10.1097/QAD.0b013e32832c4152 CrossRefPubMed

Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, Pietrzak RH (2009) Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 24:165–178. https://doi.org/10.1093/arclin/acp010 CrossRefPubMed

Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Prats A, Negredo E, Garolera M, Pérez-Alvarez N, Moltó J, Gómez G, Clotet B (2008) Nadir CD4 cell count predicts neurocognitive impairment in HIV-infected patients. AIDS Res Hum Retrovir 24:1301–1307. https://doi.org/10.1089/aid.2007.0310 CrossRefPubMed

Pavie J, Porcher R, Torti C, Medrano J, Castagna A, Valin N, Rusconi S, Ammassari A, Ghosn J, Delaugerre C, Molina JM, NEAT Unboosted Atazanavir Cohort Study Group (2011) Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virologic suppression under antiretroviral therapy. J Antimicrob Chemother 66:2372–2378. https://doi.org/10.1093/jac/dkr316 CrossRefPubMed

Robertson KR, Robertson WT, Ford S, Watson D, Fiscus S, Harp AG, Hall CD (2004) Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 36:562–566CrossRefPubMed

Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, Evans SR, Ellis RJ (2007) The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 21:1915–1921. https://doi.org/10.1097/QAD.0b013e32828e4e27 CrossRefPubMed

Robertson KR, Miyahara S, Lee A, Brown TT, Chan ES, Berzins B, Rusin D, Eron JJ, Taiwo BO, AIDS Clinical Trials Group (ACTG) 5303 team (2016) Neurocognition with maraviroc compared with tenofovir in HIV. AIDS 30:2315–2321. https://doi.org/10.1097/QAD.0000000000001189 CrossRefPubMed

Santos JR, Molto J, Llibre JM, Pérez N, Capitán MC, Clotet B (2009) Unboosted atazanavir plus co-formulated lamivudine/abacavir as a ritonavir-sparing simplification study in routine clinical practice. HIV Clin Trials 10:129–134. https://doi.org/10.1310/hct1003-129 CrossRefPubMed

Saylor D, Dickens A, Sacktor N Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC (2016) HIV-associated neurocognitive disorder- pathogenesis and prospects for treatment. Nat Rev Neurol 12:234–248. https://doi.org/10.1038/nrneurol.2016.27 CrossRefPubMedPubMedCentral

Sension M, de Andrade Neto JL, Grinsztejn B, Molina JM, Zavala I, González-García J, Donnelly A, Phiri P, Ledesma E, McGrath D, 067 Study Group (2009) Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir. J Acquir Immune Defic Syndr 51:153–162. https://doi.org/10.1097/QAI.0b013e3181a5701c CrossRefPubMed

Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, Calmy A, Chave JP, Giacobini E, Hirschel B, Du Pasquier RA (2010) Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 24:1243–1250. https://doi.org/10.1097/QAD.0b013e3283354a7b CrossRefPubMed

Smurzynski M, Wu K, Letentdre S, Robertson K, Bosch RJ, Clifford DB, Evans S, Collier AC, Taylor M, Ellis R (2011) Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 25:357–365. https://doi.org/10.1097/QAD.0b013e32834171f8 CrossRefPubMed

Soriano V, Garcia-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J (2008) Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viremia: final results of the SLOAT trial. J Antimicrob Chemother 61:200–205. https://doi.org/10.1093/jac/dkm413 CrossRefPubMed

Squires KE, Young B, DeJesus E, Bellos N, Murphy D, Zhao HH, Patel LG, Ross LL, Wannamaker PG, Shaefer MS, ARIES study team (2010) Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients. AIDS 24:2019–2027. https://doi.org/10.1097/QAD.0b013e32833bee1b CrossRefPubMed

Winston A, Duncombe C, Li PC, Gill JM, Kerr SJ, Puls R, Petoumenos K, Taylor-Robinson SD, Emery S, Cooper DA, Altair Study Group (2010) Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naïve, HIV-1–infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 50:920–929. https://doi.org/10.1086/650743 CrossRefPubMed

Winston A, Arenas-Pinto A, Stohr W, Fisher M, Orkin CM, Aderogba K, De Burgh-Thomas A, O'Farrell N, Lacey CJ, Leen C, Dunn D, Paton NI, PIVOT Trial Team (2013) Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS One 8:e61949. https://doi.org/10.1371/journal.pone.0061949 CrossRefPubMedPubMedCentral

Winston A, Puls R, Kerr SJ, Duncombe C, Li P, Gill JM, Ramautarsing R, Taylor-Robinson SD, Emery S, Cooper DA, ALTAIR Study Group (2015) Differences in the direction of change of cerebral function parameters are evident over three years in HIV-infected individuals electively commencing initial cART. PLoS One 10:e0118608. https://doi.org/10.1371/journal.pone.0118608 CrossRefPubMedPubMedCentral

Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross L, Shaefer MS (2014) Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial. PLoS One 9:e96187. https://doi.org/10.1371/journal.pone.0096187 CrossRefPubMedPubMedCentral

Wohl DA, Bhatti L, Small CB, Edelstein H, Zhao HH, Margolis DA, DeJesus E, Weinberg WG, Ross L, Shaefer MS (2016) The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir. HIV Med 17:106–117. https://doi.org/10.1111/hiv.12281 CrossRefPubMed

Zhou L, Saksena NK (2013) HIV associated neurocognitive disorders. Infect Dis Rep 5:e8. https://doi.org/10.4081/idr.2013.s1.e8 CrossRefPubMedPubMedCentral

Title: Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir
Authors: Kevin Robertson
Paul Maruff
Lisa L. Ross
David Wohl
Catherine B Small
Howard Edelstein
Mark S. Shaefer
Publication date: 01-02-2019
Publisher: Springer International Publishing
Published in: Journal of NeuroVirology / Issue 1/2019
Print ISSN: 1355-0284
Electronic ISSN: 1538-2443
DOI: https://doi.org/10.1007/s13365-018-0680-y

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir

Abstract

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Incomplete myelopathy and human T cell lymphotropic virus type-1 (HTLV-1)

Empiric neurocognitive performance profile discovery and interpretation in HIV infection

HIV-1 infection renders brain vascular pericytes susceptible to the extracellular glutamate

White matter damage, neuroinflammation, and neuronal integrity in HAND

The bovine herpesvirus 1 regulatory proteins, bICP4 and bICP22, are expressed during the escape from latency

Enhanced facilitation and diminished inhibition characterizes the pronociceptive endogenous pain modulatory balance of persons living with HIV and chronic pain